Abstract
Choroidal neovascularization membrane (CNVM) is a significant cause of ocular morbidity. Immunologic mechanisms have been proposed in the development of these lesions in exudative age related macular degeneration. Here, we describe the case of an 81-year-old man receiving ipilimumab, an immune modulating drug that enhances T cell response, for metastatic melanoma who developed three simultaneous CNVM bilaterally. This is the first case of ipilimumab-associated CNVM as well as the first case of an immune modulating drug possibly causing CNVM to our knowledge.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 341-343 |
| Number of pages | 3 |
| Journal | Cutaneous and Ocular Toxicology |
| Volume | 32 |
| Issue number | 4 |
| DOIs | |
| State | Published - Oct 2013 |
Keywords
- Age related macular degeneration
- Choroidal neovascularization
- Drug reaction
- Immunology
- Ipilimumab
- Melanoma
- T cell
ASJC Scopus subject areas
- Toxicology
Fingerprint Dive into the research topics of 'Multifocal bilateral choroidal neovascularization in a patient on ipilimumab for metastatic melanoma'. Together they form a unique fingerprint.
Cite this
Modjtahedi, B. S., Maibach, H., & Park, S. S. C. (2013). Multifocal bilateral choroidal neovascularization in a patient on ipilimumab for metastatic melanoma. Cutaneous and Ocular Toxicology, 32(4), 341-343. https://doi.org/10.3109/15569527.2013.781618